PT705099E - Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central - Google Patents
Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central Download PDFInfo
- Publication number
- PT705099E PT705099E PT94919708T PT94919708T PT705099E PT 705099 E PT705099 E PT 705099E PT 94919708 T PT94919708 T PT 94919708T PT 94919708 T PT94919708 T PT 94919708T PT 705099 E PT705099 E PT 705099E
- Authority
- PT
- Portugal
- Prior art keywords
- modafinil
- treatment
- sleep
- sec
- central origin
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229960001165 modafinil Drugs 0.000 title claims abstract description 16
- 230000000241 respiratory effect Effects 0.000 title description 5
- 201000002859 sleep apnea Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000009423 ventilation Methods 0.000 abstract 1
- 208000008784 apnea Diseases 0.000 description 15
- 206010021079 Hypopnoea Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000020020 complex sleep apnea Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000006646 mixed sleep apnea Diseases 0.000 description 1
- PKIDMDXXGGEQEM-UHFFFAOYSA-N n-benzhydrylsulfinylacetamide Chemical compound C=1C=CC=CC=1C(S(=O)NC(=O)C)C1=CC=CC=C1 PKIDMDXXGGEQEM-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307555A FR2706767B1 (enExample) | 1993-06-22 | 1993-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT705099E true PT705099E (pt) | 2002-03-28 |
Family
ID=9448411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT94919708T PT705099E (pt) | 1993-06-22 | 1994-06-14 | Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5612379A (enExample) |
| EP (1) | EP0705099B1 (enExample) |
| JP (1) | JP3703831B2 (enExample) |
| KR (1) | KR100315389B1 (enExample) |
| AT (1) | ATE207351T1 (enExample) |
| AU (1) | AU684087B2 (enExample) |
| CA (1) | CA2165824C (enExample) |
| DE (1) | DE69428791T2 (enExample) |
| DK (1) | DK0705099T3 (enExample) |
| ES (1) | ES2165878T3 (enExample) |
| FR (1) | FR2706767B1 (enExample) |
| HU (1) | HU216731B (enExample) |
| PT (1) | PT705099E (enExample) |
| WO (1) | WO1995000132A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| US20060241164A1 (en) * | 1998-02-27 | 2006-10-26 | The Board Of Trustees Of The University Of Illinoi | Pharmacological treatment for sleep apnea |
| PT1066036E (pt) | 1998-02-27 | 2006-09-29 | Univ Illinois | Agentes com actividade relacionada com serotonina para o tratamento da apneia do sono |
| US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| EP1330244B1 (en) * | 2000-10-11 | 2008-12-17 | Cephalon, Inc. | Compositions comprising modafinil compounds |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7297346B2 (en) * | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
| US7528172B2 (en) * | 2003-01-21 | 2009-05-05 | The Cooper Health System, Inc. | Compositions and methods for improving recovery after general anesthesia |
| EP1610796B1 (en) * | 2003-03-17 | 2014-04-23 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| JP2008524332A (ja) * | 2004-12-20 | 2008-07-10 | コレジウム ファーマシューティカル， インク． | 睡眠傷害のための医薬組成物 |
| US20090123545A1 (en) * | 2005-07-21 | 2009-05-14 | Ron Eyal S | Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof |
| EP2043623A4 (en) * | 2006-07-12 | 2013-03-20 | Elan Pharma Int Ltd | NANOPARTICLE FORMULATIONS OF MODAFINIL |
| WO2008021341A2 (en) | 2006-08-14 | 2008-02-21 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based treatment for premature ejaculation |
| US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
| US20100010092A1 (en) * | 2006-12-19 | 2010-01-14 | Arless Ltd. | Use of modafinil to treat restless leg syndrome |
| US20110224196A1 (en) * | 2010-01-07 | 2011-09-15 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
| CN105658227B (zh) | 2013-08-30 | 2020-04-03 | 绿十字生命健康有限公司 | 含有人参皂苷成分得到增加的加工人参粉末或加工人参提取物的用于预防及治疗癌因性疲乏的组合物 |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1993
- 1993-06-22 FR FR9307555A patent/FR2706767B1/fr not_active Expired - Fee Related
-
1994
- 1994-06-14 DK DK94919708T patent/DK0705099T3/da active
- 1994-06-14 DE DE69428791T patent/DE69428791T2/de not_active Expired - Lifetime
- 1994-06-14 JP JP50249895A patent/JP3703831B2/ja not_active Expired - Lifetime
- 1994-06-14 CA CA002165824A patent/CA2165824C/fr not_active Expired - Lifetime
- 1994-06-14 PT PT94919708T patent/PT705099E/pt unknown
- 1994-06-14 AU AU70760/94A patent/AU684087B2/en not_active Expired
- 1994-06-14 ES ES94919708T patent/ES2165878T3/es not_active Expired - Lifetime
- 1994-06-14 US US08/564,286 patent/US5612379A/en not_active Expired - Lifetime
- 1994-06-14 AT AT94919708T patent/ATE207351T1/de active
- 1994-06-14 HU HU9503702A patent/HU216731B/hu unknown
- 1994-06-14 KR KR1019950705833A patent/KR100315389B1/ko not_active Expired - Fee Related
- 1994-06-14 WO PCT/FR1994/000711 patent/WO1995000132A1/fr not_active Ceased
- 1994-06-14 EP EP94919708A patent/EP0705099B1/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2706767B1 (enExample) | 1995-09-08 |
| AU7076094A (en) | 1995-01-17 |
| DE69428791T2 (de) | 2002-07-04 |
| HU9503702D0 (en) | 1996-02-28 |
| HUT74674A (en) | 1997-01-28 |
| HU216731B (hu) | 1999-08-30 |
| ES2165878T3 (es) | 2002-04-01 |
| JPH09500374A (ja) | 1997-01-14 |
| DE69428791D1 (de) | 2001-11-29 |
| AU684087B2 (en) | 1997-12-04 |
| CA2165824C (fr) | 2005-08-02 |
| WO1995000132A1 (fr) | 1995-01-05 |
| ATE207351T1 (de) | 2001-11-15 |
| FR2706767A1 (enExample) | 1994-12-30 |
| EP0705099A1 (fr) | 1996-04-10 |
| US5612379A (en) | 1997-03-18 |
| DK0705099T3 (da) | 2002-02-11 |
| KR100315389B1 (ko) | 2002-02-19 |
| JP3703831B2 (ja) | 2005-10-05 |
| EP0705099B1 (fr) | 2001-10-24 |
| CA2165824A1 (fr) | 1995-01-05 |
| KR960703009A (ko) | 1996-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT705099E (pt) | Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central | |
| Taranto-Montemurro et al. | The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial | |
| Strohl et al. | Progesterone administration and progressive sleep apneas | |
| Becker et al. | Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure. | |
| Villa et al. | Randomized controlled study of an oral jaw-positioning appliance for the treatment of obstructive sleep apnea in children with malocclusion | |
| Mamelak et al. | Treatment of narcolepsy and sleep apnea with gammahydroxybutyrate: a clinical and polysomnographic case study | |
| Guilleminault et al. | From apnea of infancy to obstructive sleep apnea syndrome in the young child | |
| CN107007602A (zh) | 治疗阻塞性睡眠呼吸暂停的方法 | |
| Goff et al. | The cardiovascular response to arousal from sleep decreases with age in healthy adults | |
| Rollinson et al. | Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate | |
| Sanford et al. | Pretreatment with sedative-hypnotics, but not with nondepolarizing muscle relaxants, attenuates alfentanil-induced muscle rigidity | |
| Goold | Postoperative spasticity and shivering: a review with personal observations of 500 patients | |
| Dai et al. | Comparative evaluation of intravenous versus intranasal dexmedetomidine on emergence delirium and hemodynamics in pediatric patients undergoing adenotonsillectomy: a randomized controlled trial | |
| Padda et al. | Comparison of postoperative emesis, recovery profile, and analgesia in pediatric strabismus repair: rectal acetaminophen versus intravenous fentanyl-droperidol | |
| Steegers et al. | Propofol in total intravenous anaesthesia without nitrous oxide | |
| Samuels et al. | Difficulty reversing drug-induced coma in a patient with sleep apnea | |
| IL261984A (en) | Sultiame for the treatment of sleep apnea | |
| APPLETON et al. | A Neuroinhibitory Substance: Gamma Hydroxybutyric Acid preliminary report of first clinical trial in Britain | |
| Montgomery et al. | Marked suppression of ventilation while awake following massive ingestion of atenolol | |
| Cangemi Jr | Administration of general anesthesia for outpatient orthognathic surgical procedures | |
| Miller et al. | a preliminary report on THE USE OF INTRAMUSCULAR METHOHEXITAL SODIUM (BREVITAL®) FOR PEDIATRIC ANESTHESIA | |
| Searle et al. | Hemodynamic and pharmacodynamic comparison of doxacurium and high-dose vecuronium during coronary artery bypass surgery: a cost-benefit study | |
| SINGH et al. | Efficiency of Magnesium Sulphate as a Sole Muscle Relaxant for General Anaesthesia with Vecuronium Bromide for Tracheal Intubation: A Prospective Interventional Study. | |
| Leoni et al. | Pain control with low-dose alfentanil in children undergoing minor abdominal and genito-urinary surgery | |
| Sivathondan | Myotonic dystrophy and pain management of a patient undergoing total abdominal hysterectomy in a metropolitan general hospital |